Coherus Oncology Pivots to Immuno-Oncology, Touts LOQTORZI Growth and New Pipeline at Citizens Conf.

He described LOQTORZI as a “next-gen” PD-1 with high-affinity binding and a mechanism that results in internalization of PD-1 from the T-cell surface, which he said has translated into activity in low PD-L1 cancers. As one example, he noted LOQTORZI is labeled in the European Union for low PD-L1 esophageal cancer, while KEYTRUDA and OPDIVO have lost U.S. labels in low PD-L1 esophageal cancer.Lanfear positioned LOQTORZI (toripalimab) as both a revenue generator in metastatic nasopharyngeal carcinoma and a “r ...